Cybin
HELP8.1402.91% ( +0.230 )
Cybin (HELP)
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurologic...
- Open
- 7.970
- High
- 8.190
- Low
- 7.880
- Prev. Close
- 7.910
- Volume
- 861.17K
- Turnover
- 6.92M
- Avg Price
- 8.036
- Bid/Ask Ratio
- --
- Amplitude
- 3.92%
- 52wk High
- 9.120
- Volume Ratio
- 0.23
- Turnover Ratio
- 1.84%
Cybin Analyst Rating
View MoreForecast & Rating
Jul 27, 2026Price forecast
$35.18332.21%
Forecast & RatingStrong buy
10analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Jul 27 at 09:14 AM
Cybin Inc. (NASDAQ:HELP) Receives Average Recommendation of "Buy" from Analysts
- Tip Ranks · Jul 21 at 04:51 PM
Helus Pharma Fast-Tracks Phase 3 Enrollment for MDD Drug HLP003
- PR Newswire · Jul 17 at 07:50 AM
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- StockTitan · Jul 15 at 09:45 PM
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions | LLY Stock News
- benzinga_article · Jul 16 at 02:18 AM
UnitedHealth, Abbott Laboratories And 3 Stocks To Watch Heading Into Thursday
- PUBT · Jun 29 at 07:23 AM
Cybin publishes corporate presentation on HLP003, deuterated serotonergic agonist for major depressive disorder
